rs368404711
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM2PM5PP3PP5
The NM_000092.5(COL4A4):c.5045G>A(p.Arg1682Gln) variant causes a missense change. The variant allele was found at a frequency of 0.0000725 in 1,614,058 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R1682W) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000092.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL4A4 | NM_000092.5 | c.5045G>A | p.Arg1682Gln | missense_variant | 48/48 | ENST00000396625.5 | NP_000083.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL4A4 | ENST00000396625.5 | c.5045G>A | p.Arg1682Gln | missense_variant | 48/48 | 5 | NM_000092.5 | ENSP00000379866 | P1 | |
COL4A4 | ENST00000682098.1 | c.647G>A | p.Arg216Gln | missense_variant | 3/3 | ENSP00000508331 |
Frequencies
GnomAD3 genomes AF: 0.0000920 AC: 14AN: 152168Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000124 AC: 31AN: 249590Hom.: 0 AF XY: 0.000111 AC XY: 15AN XY: 135410
GnomAD4 exome AF: 0.0000705 AC: 103AN: 1461890Hom.: 0 Cov.: 29 AF XY: 0.0000784 AC XY: 57AN XY: 727246
GnomAD4 genome AF: 0.0000920 AC: 14AN: 152168Hom.: 0 Cov.: 33 AF XY: 0.000108 AC XY: 8AN XY: 74328
ClinVar
Submissions by phenotype
not provided Pathogenic:2Uncertain:2
Likely pathogenic, no assertion criteria provided | research | Gharavi Laboratory, Columbia University | Sep 16, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Feb 27, 2024 | Reported without a second variant in unrelated patients with thin basement nephropathy (PMID: 17216251, 26809805); Reported with a COL4A3 variant in unrelated families with features of Alport syndrome in published literature; some relatives heterozygous for only the COL4A4 variant presented with milder features (PMID: 27859054, 29801666, 33838161); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 17216251, 27859054, 26809805, 30586318, 29801666, 33838161, 37248651, 36100708) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Nov 25, 2020 | PP3 - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 22, 2024 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1682 of the COL4A4 protein (p.Arg1682Gln). This variant is present in population databases (rs368404711, gnomAD 0.2%). This missense change has been observed in individuals with hematuria and thin basement membrane nephropathy (PMID: 17216251, 26809805, 27859054). ClinVar contains an entry for this variant (Variation ID: 447192). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on COL4A4 protein function. This variant disrupts the p.Arg1682 amino acid residue in COL4A4. Other variant(s) that disrupt this residue have been observed in individuals with COL4A4-related conditions (PMID: 21897443), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jun 07, 2017 | - - |
COL4A4-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 01, 2022 | The COL4A4 c.5045G>A variant is predicted to result in the amino acid substitution p.Arg1682Gln. This variant was reported in the heterozygous state in two individuals with thin basement membrane nephropathy (Rana et al. 2007. PubMed ID: 17216251; Weber et al. 2016. PubMed ID: 26809805). This variant was interpreted as likely pathogenic for autosomal dominant Alport syndrome based on ACMG criteria (Table S1, Furlano et al, 2021PubMed ID: 33838161). This variant was also reported in the heterozygous state along with a missense variant in COL4A3 in two individuals with Alport syndrome, with a proposed digenic inheritance (Fallerini et al. 2017. PubMed ID: 27859054; Table S3, Bullich. 2018. PubMed ID: 29801666). Of note, an affected sibling of the proband also carried the COL4A4 c.5045G>A (p.Arg1682Gln), but did not have the COL4A3 variant;. A nephew of the proband, who had proteinuria, was negative for both the COL4A4 c.5045G>A (p.Arg1682Gln) and the COL4A3 variant (Table 1, Fallerini et al. 2017. PubMed ID: 27859054). This variant is reported in 0.20% of alleles in individuals of Ashkenazi Jewish descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-227872069-C-T) and has conflicting interpretations of pathogenicity in ClinVar ranging from uncertain to likely pathogenic (http://www.ncbi.nlm.nih.gov/clinvar/variation/447192). Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at